Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloomston, M.
Right arrow Articles by Rosemurgy, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloomston, M.
Right arrow Articles by Rosemurgy, A. S., II
Related Collections
Right arrow Other Pancreas
Annals of Surgical Oncology 9:668-674 (2002)
© 2002 Society of Surgical Oncology

ORIGINAL ARTICLES

Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials

Mark Bloomston, MD, Emmanuel E. Zervos, MD and Alexander S. Rosemurgy, II, MD

From the Department of Surgery, University of South Florida, Tampa, Florida.

Correspondence: Address correspondence and reprint requests to: Alexander S. Rosemurgy II, MD, Department of Surgery, University of South Florida, PO Box 1289, Room F-145, Tampa, FL 33601; Fax: 813-844-7396; E-mail: arosemur{at}hsc.usf.edu

Abstract: Matrix metalloproteinases (MMPs) have received much attention in recent years for their role in a variety of malignancies. Pancreatic cancer is no exception; MMP-2 and MMP-9 show high levels of expression in clinical and experimental models. Inhibition of MMPs has shown great promise with synthetic inhibitors, such as BB-94, as tumorostatic agents in preclinical models, particularly when these are combined with gemcitabine. These findings have led to several clinical trials using the MMP inhibitors Marimastat and BAY12-9566. Herein, we discuss the roles of MMPs and their inhibition in pancreatic cancer.

Key Words: Pancreatic cancer • Matrix metalloproteinase • MMP • TIMP




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Egami, K. Ohuchida, K. Mizumoto, M. Onimaru, H. Toma, S. Nishio, E. Nagai, K. Matsumoto, T. Nakamura, and M. Tanaka
Radiation Enhances Adenoviral Gene Therapy in Pancreatic Cancer via Activation of Cytomegalovirus Promoter and Increased Adenovirus Uptake
Clin. Cancer Res., March 15, 2008; 14(6): 1859 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C.-S. Huang, J.-W. Liao, and M.-L. Hu
Lycopene Inhibits Experimental Metastasis of Human Hepatoma SK-Hep-1 Cells in Athymic Nude Mice
J. Nutr., March 1, 2008; 138(3): 538 - 543.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. Ahmad, S. Attoub, M. N. Singh, F. L. Martin, and O. M. A. El-Agnaf
{gamma}-Synuclein and the progression of cancer
FASEB J, November 1, 2007; 21(13): 3419 - 3430.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. G. Spinale, G. P. Escobar, J. W. Hendrick, L. L. Clark, S. S. Camens, J. P. Mingoia, C. G. Squires, R. E. Stroud, and J. S. Ikonomidis
Chronic Matrix Metalloproteinase Inhibition Following Myocardial Infarction in Mice: Differential Effects on Short and Long-Term Survival
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 966 - 973.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Kumar, Z.-R. Liu, L. Thapa, and R.-Y. Qin
Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts
Carcinogenesis, November 1, 2004; 25(11): 2075 - 2081.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. C.L. Schuh
Trials, Tribulations, and Trends in Tumor Modeling in Mice
Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society of Surgical Oncology.